Antirheumatic agents in covid-19: is IL-6 the right target?

Ann Rheum Dis. 2021 Jan;80(1):e2. doi: 10.1136/annrheumdis-2020-217523. Epub 2020 Apr 16.

¹ Department of Medical Sciences, Surgery and Neurosciences, Section of Internal Medicine, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy capecchipl@unisi.it.
² Department of Medical Sciences, Surgery and Neurosciences, Section of Internal Medicine, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.
³ Department of Medical Sciences, Surgery and Neurosciences, Section of Radiology, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.
⁴ Section of Infectious Diseases, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.
⁵ Department of Medical Biotechnologies, Section of Infectious Diseases, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.
⁶ Section of Pneumology, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.
⁷ Department of Medical Sciences, Surgery and Neurosciences, Section of Pneumology, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.
⁸ Department of Medical Sciences, Surgery and Neurosciences, Section of Intensive Care, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.
⁹ Department of Medical Biotechnologies, Section of Cardiology, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.
¹⁰ Section of Cardiology, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.
¹¹ Department of Medical Sciences, Surgery and Neurosciences, Section of Rheumatology, COVID-19 Unit, Siena University Hospital, Siena, Toscana, Italy.

No abstract available

Keywords: antirheumatic agents; cardiovascular diseases; inflammation; patient care team.

Publication types